Abstract
Neoadjuvant chemoradiation therapy followed by the surgical resection of residual disease has become the most common treatment strategy for locally advanced disease despite the lack of a convincing phase III trial supporting this treatment approach. This year’s ASCO meeting saw the presentation of the first results of neoadjuvant chemoradiotherapy replacing old drugs such as Cisplatin by newer substances such as Oxaliplatin, Docetaxel and the integration of biological agents into the preoperative approach.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
